Back to today’s briefing

Story perspectives

Boston Scientific Shares Plunge 18% Amid Q4 Earnings Concerns

2/5/2026

50 8 Full Breakdown

Summary

Story summary

Boston Scientific shares fell nearly 18% after the company reported its Q4 2025 earnings.
The company posted revenue of $5.29 billion and adjusted EPS of $0.80 and issued 2026 guidance of 10-11% organic growth.
Electrophysiology underperformed, raising concerns about market share loss and prompting CEO Mike Mahoney to cite ongoing innovation and Penumbra-driven growth to reassure investors awaiting clinical data and acquisition integration.

History

Historical Context

The 2008 financial crisis triggered a 37% decline in the S&P 500, impacting companies like Boston Scientific, which reported $5.29 billion in revenue that year. This revenue reflected a recovery in the medical device industry, yet Boston Scientific's 18% stock drop underscored investor concerns about competition and innovation, echoing patterns seen during previous economic downturns.

1 of 2

Story summary

Boston Scientific shares fell nearly 18% after the company reported its Q4 2025 earnings.
The company posted revenue of $5.29 billion and adjusted EPS of $0.80 and issued 2026 guidance of 10-11% organic growth.
Electrophysiology underperformed, raising concerns about market share loss and prompting CEO Mike Mahoney to cite ongoing innovation and Penumbra-driven growth to reassure investors awaiting clinical data and acquisition integration.

1 / 2